| Year Approved** | ||||
| Drug (INN)* | Trade Name | Developer | FDA | Europe |
| Gemtuzumab Ozogamicin | Maylotarg® | Wyeth/Pfizer | 2000 (Witdrawn) | 2000 (Witdrawn) |
| Gemtuzumab Ozogamicin | Maylotarg® | Wyeth/Pfizer | 2017 (Reintroduced) | |
| Brentuximab Vedodin | Adcetris® | Seattle Genetics / Takeda | 2011 | 2012 |
| Ado-trastuzumab emtansine | Kadcyla® | Genentech/Roche | 2013 | 2013 |
| Inotuzumab Ozogamicin | Besponsa® | Wyeth/Pfizer | 2017 | 2017 |
| Polatuzumab vedotin-piiq | Polivy™ | Genentech/Roche | 2019 | |
* Link to drug description
** Link to package insert
